首页> 美国卫生研究院文献>other >Antigen coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations
【2h】

Antigen coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations

机译:基于抗原涂覆聚α-羟基酸的异源性初级 - 升压腺病毒基疫苗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adenoviruses show promising potential as vectors for cancer vaccines, however, their high immunogenicity can be problematic when it comes to homologous prime-boost strategies. In the studies presented here we show that heterologous prime-boost vaccinations involving ovalbumin (OVA)-antigen coated microparticles as a prime, and adenovirus encoding OVA (Ad-OVA) as a boost, were equally as effective as homologous Ad-OVA prime-boosts at generating OVA-specific CD8+ T cell responses, which translated into effective tumor protection. OVA-coated biodegradable poly α-hydroxy acid based microparticles of varying chemistries, when used as primes in heterologous prime-boost vaccinations, were comparable in terms of promoting OVA-specific CD8+ T cells as well as providing protection against subsequent tumor challenge. These findings auger well for using poly α-hydroxy acid based microparticles in prime-boost viral vaccination strategies geared toward the safer, and potentially more efficient, generation of anti-tumor immunity.
机译:腺病毒作为癌症疫苗的载体显示出有希望的潜力,但是,当涉及同源初免-加强策略时,腺病毒的高免疫原性可能会成问题。在此处提出的研究中,我们显示异源的初免-加强疫苗接种以卵清蛋白(OVA)-抗原包被的微粒为初次接种,而编码OVA(Ad-OVA)的腺病毒作为加强疫苗,与同源Ad-OVA初次接种同样有效。促进产生OVA特异性CD8 + T细胞应答,从而转化为有效的肿瘤保护。当用作异源初免-加强接种疫苗的初免剂时,不同化学性质的OVA包被的可生物降解的聚α-羟基酸基微粒在促进OVA特异性CD8 + T细胞以及提供针对后续肿瘤攻击的保护方面具有可比性。这些发现很好地说明了基于聚α-羟基酸的微粒在初免-加强型病毒疫苗接种策略中的应用,旨在实现更安全,可能更有效的抗肿瘤免疫力的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号